Aankondiging • Mar 05
Euroapi S.A. Provides Earnings Guidance for the Fy 2026 Euroapi S.A. provided earnings guidance for the Fiscal Year 2026. For the period, the company expects Net Sales to decrease around 10% on a comparable basis compared to 2025 due to the negative impact of portfolio rationalization (€(55) to (60) million negative impact expected in 202615), reduced demand from Sanofi, and the discontinuation of commercial CDMO contracts. Aankondiging • Oct 02
EUROAPI Announces Step Down of Rodolfo J. Savitzky as Independent Director and Chair of the Audit Committee, Effective December 31, 2025 EUROAPI announced that Rodolfo J. Savitzky will step down from his role as EUROAPI’s Independent Director and Chair of the Audit Committee, effective December 31, 2025. The search for a new Independent Director has been initiated, and Rodolfo J. Savitzky’s successor is expected to be appointed before the end of the year. Aankondiging • Jul 02
Particle Dynamics, Inc. acquired EUROAPI UK Ltd from Euroapi S.A. (ENXTPA:EAPI). Particle Dynamics, Inc. acquired EUROAPI UK Ltd from Euroapi S.A. (ENXTPA:EAPI) on June 30, 2025. The transaction was completed under financial terms reflecting the fair value of the shares sold. All operations and associated commitments related
to the company will be transferred to Particle Dynamics.
The transaction is expected to have a limited impact on EUROAPI’s H1 2025 consolidated financial statements.
Particle Dynamics, Inc. completed the acquisition of EUROAPI UK Ltd from Euroapi S.A. (ENXTPA:EAPI) on June 30, 2025. Aankondiging • Apr 17
Euroapi S.A., Annual General Meeting, May 21, 2025 Euroapi S.A., Annual General Meeting, May 21, 2025. Location: theatre traversiere, 15 bis rue traversiere, paris France Aankondiging • Mar 04
Euroapi S.A. Provides Earnings Guidance for the Full Year 2025 Euroapi S.A. provided earnings guidance for the full year 2025. For the year, the company expects Net Sales are expected to range from slightly decreasing to steady. This should notably be driven by solid growth in API sales to clients other than Sanofi, particularly in HP APIs, and Opiates, and by double-digit growth in sales from early-phase CDMO, offset by continued reduced API demand from Sanofi, particularly for Sevelamer, a slight decrease in Vitamin B12 sales, and the discontinuation of several pre-carve-out mature CMO projects. Aankondiging • Sep 13
Euroapi S.A. to Report Fiscal Year 2024 Results on Mar 03, 2025 Euroapi S.A. announced that they will report fiscal year 2024 results on Mar 03, 2025 Aankondiging • Apr 10
Euroapi S.A. Announces Executive and Executive Committee Changes EUROAPI announced a streamlining of its Executive Committee around operational functions in order to improve focus and efficiency. As part of this move, Guillaume Rosso has been appointed as Chief Commercial Officer, succeeding Laurent Alexandre who has decided to pursue other opportunities outside of the company. The new Executive Committee will be composed of: Antoine Delcour,Chief Financial Officer, Thierry Durand,Chief R&D Officer, Ute Herzog, Chief Human Resources Officer, Cécile Maupas, Chief CDMO Officer, Guillaume Rosso, Chief Commercial Officer, David Seignolle, Chief Operating Officer. New Risk • Mar 06
New minor risk - Financial position The company has less than a year of cash runway based on its current free cash flow. Free cash flow: -€128m This is considered a minor risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Shares are highly illiquid. Minor Risk Less than 1 year of cash runway based on current free cash flow (-€128m). Board Change • Mar 06
High number of new and inexperienced directors There are 12 new directors who have joined the board in the last 3 years. The company's board is composed of: 12 new directors. No experienced directors. No highly experienced directors. Nominating Director Adeline Franc is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Aankondiging • Nov 29
EUROAPI Announces Executive Changes EUROAPI announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization, focusing on reinforcing robustness and compliance on the entire end-to-end supply chain whilst bringing relevant innovation and product development to support the company's ambition. He will actively oversee the industrial execution of the strategic review announced on October 9, 2023. David Seignolle, a French citizen, joins EUROAPI from Bain & Company where he served as Expert Partner in the Healthcare Practice. Prior to this, David spent 6 years at TEVA where he held several positions such as Head of Operations for Teva API in Italy and Mexico, Vice President Global Supply Chain API and Biologics or Site General Manager. David has also served 5 years at McKinsey & Company in France and in the US where he was focusing on Pharma Operations after beginning his career in Procurement at Toyota Motor Europe. David has a degree in Mechanical Engineering & Industrial Science as well as a postmaster degree in International Procurement Management. Marion Santin, a French citizen, began her career as an associate in law firms, first at Kramer Levin Naftalis & Frankel LLP and then at DLA Piper. She then joined Sanofi in 2006, where she first held the position of Industrial Affairs Legal Manager, then Alliances & Partnerships Legal Director, Mergers & Acquisitions Legal Director before becoming Commercial Operations Legal Director for the legal teams based in Asia, the Middle East, India, Hong Kong and Taiwan. Marion holds an Advanced Degree in Business Law and a Magistère in Business Law from the University of Paris I - Panthéon-Sorbonne. Marion is also a member of the Paris Bar. Aankondiging • Nov 22
Euroapi S.A. (ENXTPA:EAPI) completed the acquisition of Bianogmp Gmbh. Euroapi S.A. (ENXTPA:EAPI) signed an agreement to acquire Bianogmp Gmbh for €10 million on August 29, 2023. The total consideration for the transaction is approximately €10 million, including the acquisition price (upfront payment and deferred consideration) and Capex aimed to increase Biano’s capacity to address larger scale and more complex projects. Biano will retain its corporate brand and become a EUROAPI company. The closing of the transaction is subject to customary conditions precedent and is expected in the fourth quarter of 2023.Euroapi S.A. (ENXTPA:EAPI) completed the acquisition of Bianogmp Gmbh on November 21, 2023. As planned, Biano will retain its corporate brand and become a EUROAPI company. Valuation Update With 7 Day Price Move • Oct 11
Investor sentiment deteriorates as stock falls 53% After last week's 53% share price decline to €5.53, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 15x in the Pharmaceuticals industry in the United Kingdom. Total loss to shareholders of 69% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €9.63 per share. Aankondiging • Oct 10
Euroapi S.A. Provides Sales Guidance for the Full-Year 2023 Euroapi S.A. provided sales guidance for the full-year 2023. For the year Net Sales are now expected to grow between +3% and +5%, compared to +7% to +8% previously. The slowdown of full-year 2023 Net Sales growth compared to initial expectations is primarily driven by: For API Solutions: the price optimization strategy has recently been impaired by the changing market environment, with pricing pressure resulting from lower overall inflation and destocking programs from some of customers. For the CDMO activities: Net Sales are expected to grow at a slower pace than anticipated due to weaker sales recognition than expected in the fourth quarter. This is notably driven by Biotech companies, with projects delayed, put on hold, or downsized due to funding issues. Aankondiging • Aug 31
Euroapi S.A. (ENXTPA:EAPI) signed an agreement to acquire Bianogmp Gmbh for €10 million. Euroapi S.A. (ENXTPA:EAPI) signed an agreement to acquire Bianogmp Gmbh for €10 million on August 29, 2023. The total consideration for the transaction is approximately €10 million, including the acquisition price (upfront payment and deferred consideration) and Capex aimed to increase Biano’s capacity to address larger scale and more complex projects. Biano will retain its corporate brand and become a EUROAPI company. The closing of the transaction is subject to customary conditions precedent and is expected in the fourth quarter of 2023. Reported Earnings • Aug 02
First half 2023 earnings released: EPS: €0.67 (vs €0.18 in 1H 2022) First half 2023 results: EPS: €0.67 (up from €0.18 in 1H 2022). Revenue: €498.5m (up 2.6% from 1H 2022). Net income: €62.8m (up 276% from 1H 2022). Profit margin: 13% (up from 3.4% in 1H 2022). Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Pharmaceuticals industry in the United Kingdom. Reported Earnings • Mar 10
Full year 2022 earnings released Full year 2022 results: Revenue: €980.9m (up 9.9% from FY 2021). Net loss: €15.0m (loss narrowed 5.1% from FY 2021). Revenue is forecast to grow 5.2% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Pharmaceuticals industry in the United Kingdom. Aankondiging • Jan 12
EUROAPI Announces Resignation of Corinne Le Goff as an Independent Member on the Board of Directors The board of directors of EUROAPI announced Corinne Le Goff, after serving as an independent member on the board of directors since May 6, 2022, has resigned from her directorship as of January 11, 2023. Buying Opportunity • Dec 08
Now 29% undervalued after recent price drop Over the last 90 days, the stock is down 13%. The fair value is estimated to be €20.26, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 5.4% per annum. Earnings is also forecast to grow by 32% per annum over the same time period. Buying Opportunity • Nov 17
Now 20% undervalued Over the last 90 days, the stock is up 9.1%. The fair value is estimated to be €21.98, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 5.4% per annum. Earnings is also forecast to grow by 31% per annum over the same time period. Aankondiging • Sep 01
Euroapi S.A. to Report Fiscal Year 2022 Results on Mar 08, 2023 Euroapi S.A. announced that they will report fiscal year 2022 results Pre-Market on Mar 08, 2023 
